This is a Validated Antibody Database (VAD) review about mouse Cxadr, based on 7 published articles (read how Labome selects the articles), using Cxadr antibody in all methods. It is aimed to help Labome visitors find the most suited Cxadr antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Cxadr synonym: 2610206D03Rik; AU016810; AW553441; CAR; MCAR; MCVADR

EMD Millipore
mouse monoclonal (RmcB)
  • flow cytometry; human; loading ...
EMD Millipore Cxadr antibody (Millipore, RmcB) was used in flow cytometry on human samples . Cancer Gene Ther (2020) ncbi
mouse monoclonal (RmcB)
  • flow cytometry; human; 1:500; loading ...; fig 10
In order to identify human cytomegalovirus genes within the US12 family containing novel natural killer cell evasion functions, EMD Millipore Cxadr antibody (Merck Millipore, 05-644) was used in flow cytometry on human samples at 1:500 (fig 10). elife (2017) ncbi
mouse monoclonal (RmcB)
  • flow cytometry; human; tbl 3
In order to show the feasibility of adenoviral retargeting of tumor cells using the GRP78-binding peptide, EMD Millipore Cxadr antibody (millipore, 05-644) was used in flow cytometry on human samples (tbl 3). Cancer Gene Ther (2016) ncbi
mouse monoclonal (RmcB)
  • blocking or activating experiments; human; 1:100
EMD Millipore Cxadr antibody (Upstate, RmcB) was used in blocking or activating experiments on human samples at 1:100. PLoS Pathog (2015) ncbi
mouse monoclonal (RmcB)
  • flow cytometry; human
EMD Millipore Cxadr antibody (Upstate Cell Signaling Solutions, RmcB) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (RmcB)
  • flow cytometry; human
EMD Millipore Cxadr antibody (Millipore, RmcB) was used in flow cytometry on human samples . J Gene Med (2013) ncbi
mouse monoclonal (RmcB)
  • flow cytometry; human; 1:250
EMD Millipore Cxadr antibody (Upstate Biotechnologies, 05-644) was used in flow cytometry on human samples at 1:250. Cancer Gene Ther (2007) ncbi
Articles Reviewed
  1. Hulin Curtis S, Davies J, Nestić D, Bates E, Baker A, Cunliffe T, et al. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Ther. 2020;: pubmed publisher
  2. Fielding C, Weekes M, Nobre L, Růcková E, Wilkie G, Paulo J, et al. Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. elife. 2017;6: pubmed publisher
  3. Kaliberov S, Kaliberova L, Yan H, Kapoor V, Hallahan D. Retargeted adenoviruses for radiation-guided gene delivery. Cancer Gene Ther. 2016;23:303-14 pubmed publisher
  4. Lenman A, Liaci A, Liu Y, Årdahl C, Rajan A, Nilsson E, et al. Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cells. PLoS Pathog. 2015;11:e1004657 pubmed publisher
  5. Majhen D, Stojanović N, Vukić D, Pichon C, Leduc C, Osmak M, et al. Increased adenovirus Type 5 mediated transgene expression due to RhoB down-regulation. PLoS ONE. 2014;9:e86698 pubmed publisher
  6. Janssen J, Liu J, Skokan J, Gonçalves M, de Vries A. Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells. J Gene Med. 2013;15:1-11 pubmed publisher
  7. Kasman L, Lu P, Voelkel Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007;14:327-34 pubmed